Reclaim
what’s yours.
For patients, it’s about reclaiming what hair loss has taken. For our investors, it’s about the credible prospect of turning early conviction into meaningful returns. aevX Bio brings together validated therapeutic biology and PLGA microsphere technology to develop differentiated, long-acting treatments for hair loss, a condition affecting around half of the global population, with significant personal impact and strong out-of-pocket demand.
The aevX Bio.
Opportunity snapshot.
6Bn Serviceable Available Market
Global androgenetic alopecia treatment market, 2023–2030, growing at ~8.5% CAGR.
US$300–600M
Annual revenue potential, assuming penetration of only 5-10% of the serviceable available market.
3–5 years
Revenue horizon, with a time- and capital-efficient development path to clinical and commercial milestones.
Development Roadmap
Why aevX Bio
Best-in-class product ambition
Aiming for efficacy of oral drugs, safety of a local therapy, with twice-yearly rather than daily treatment.
Built for adoption
Clear physician and patient pull, addressing today’s treatment trade-offs through a physician-administered route already familiar in practice.
